Giampaolo Bianchini

Request an appointment

Specialty:

Oncology Breast Oncology

Profession:

Oncologist

Location:

Department of Clinical Oncology @ Ospedale San Raffaele

Languages:

Request an appointment

Biography

Dr. Giampaolo Bianchini is the leading specialist in breast oncology in the Department of Clinical Oncology at the Ospedale San Raffaele.

In 2000, Dr. Bianchini graduated from the Faculty of Medicine and Surgery at the University of Milan-Bicocca, and later he completed his specialization in Clinical Oncology at the University of Milan in 2004. In the beginning of his career as a visiting research fellow, he took part in various prestigious American institutions such as the National Cancer Institute (Bethesda), MD Anderson Cancer Center (Houston) and Yale Cancer Center (New Haven).

With 20 years of experience, Dr. Bianchini specializes in treating patients with early and metastatic breast carcinoma.

Movreover, he leads a team for Immunotherapy and Translational Clinical Research at the Department of Clinical Oncology and is actively involved in numerous research projects for women with breast carcinoma conducted for understanding the response mechanisms and resistance to existing drugs, identifying new therapeutic strategies, and biomarkers which helps to choose an individual treatment.

Dr. Bianchini also participates in studies aimed at identifying the mechanisms of response and resistance to immunotherapeutic drugs, as well as in the development of clinical trials for their use in the treatment of breast carcinoma and many other solid tumors.

Dr. Bianchini has an H-index equal to 22 thanks to numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology, which makes him a recognized expert in their field.

Education

University of Milan Bicocca

Degree in Medicine and Surgery – 2000

University of Milan Bicocca

Medical Oncology Specialization – 2004

Multimedia gallery

Triple-negative breast cancer: new hope

Do you need an appointment?

Request an appointment

Publications

Dr. Bianchini is the author of numerous publications in international journals such as the Journal Clinical Oncology, Lancet Oncology, Cancer Cell, Journal National Cancer Institute, JAMA Oncology and Annals of Oncology. Its H index is 22. He regularly participates in national and international congresses and symposia.

Latest publications

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

J Clin Oncol 28:4316-23, 2010

Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

Cancer Res 70:8852-62, 2010

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang C, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WK, Gianni L, Pusztai L.

Biological processes associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.

J Natl Cancer Inst 2010 Dec 29

Iwamoto T, Bianchini G, Booser D, QI Y, Coutant C, Shiang C, Santarpia L, Matsuoka J, Hortobagyi GN, Symmans WF, Holmes F, O'Shaughnessy J, Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai

Breast cancer genomics: challenges in interpretation and application.

Oncologist. 2013;18(4):e11-2

Kelly CM, Symmans WF, Andreopoulou E, Bianchini G

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers.

Breast Cancer Research 2013 15:R86

Bianchini G*, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly CM, Muller V, Schmidt M, Qi Y, Holtrich U, Becker S, Santarpia L, Angelica F, Del Conte G, Zambetti M, Sotiriou C, Haibe-Kains B, Symmans WF, Gianni L

An unmeet need: tailoring extended adjuvant endocrine therapy

British Journal of Cancer (2013), 1–4

Bianchini G, Gianni L

The immune system and response to her2-targeted therapy in breast cancer.

The Lancet Oncology (2014) 15:e58-e68

Bianchini G, Gianni L

Research-based pam50 subtype predictor identifies higher responses and improved survival outcomes in her2-positive breast cancer in the noah study.

Clin Cancer Res (2014) 20:511-21, 2014

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez V, Gianni L, Baselga J

Immune modulation of pathologic complete response after neoadjuvant her2-directed therapies in the neosphere trial.

Annals of Oncology 26(12): 2429-36

Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi GV, Tseng L-M, Liu M-C, Lluch A, Galeota E, Magazzù D, Rodríguez J, Oh D-Y, Poirier B, Pedrini JL, Semiglazov V, Valagussa P, Gianni L

Subtype specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer.

Clinical Cancer Research 22(2): 337-45

Callari M, Cappelletti V, D'Aiuto F, Musella V, Lembo A, Petel F, Karn T, Iwamoto T, Provero P, Daidone MG, Gianni L, Bianchini G*

New strategies in breast cancer: immunotherapy.

Clin Cancer Res 22(9): 2105-10

Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Nat Rev Clin Oncol Nov;13(11):674-690.

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L

Biomarker analysis of the neosphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of her2-positive breast cancer.

Breast Cancer Res 19(1): 16

Bianchini G, Kiermaier A, Bianchi GV, Im YH, Pienkowski T, Liu MC, Tseng LM, Dowsett M, Zabaglo L, Kirk S, Szado T, Eng-Wong J, Amler LC, Valagussa P, Gianni L

Association between genomic metrics and immune infiltration in triple-negative breast cancer.

JAMA Oncology (doi:10.1001/jamaoncol.2017.2140)

Karn T, Jiang T, Hatzis C, Sänger N, El-Balat A, Rody A, Holtrich U, Becker S, Bianchini G, Pusztai L

Is trastuzumab single agent obsolete in eraly breast cancer? No.

Breast. 2019 Feb;43:142-145

Bianchini G

Do you need an appointment?

Request an appointment